Above all members of this large family, RANKL and its RANK receptor are major targets in the development of new therapies for bone-metabolism diseases, such as osteoporosis, tooth loss, arthritis, or cancer bone metastases [3]. This evidence concerns the gene TNFSF11 and osteoporosis.